Literature DB >> 3397971

A prospective study comparing incisional labial to incisional parotid biopsies in the detection and confirmation of sarcoidosis, Sjögren's disease, sialosis and lymphoma.

R E Marx1, K S Hartman, K V Rethman.   

Abstract

Simultaneous incisional biopsies of labial minor salivary glands and the superficial lobe of the parotid were accomplished in patients suspicious for sarcoidosis, Sjögren's disease, sialosis and lymphomatous changes in Sjögren's disease. Labial minor salivary gland biopsies identified sarcoidosis in 11 of 31 (36%) patients, compared to 29 of 31 (93%) patients using the parotid biopsy (p = 0.005). Similarly, the labial minor salivary gland biopsy confirmed 21 of 36 (58%) patients to have Sjögren's disease, compared to 36 of 36 (100%) (p = 0.005) patients confirmed using the parotid biopsy. Five patients with normal labial salivary gland biopsies were shown to have idiopathic hypertrophic sialosis with enlarged parotids identified by the parotid biopsy. Five additional patients were diagnosed with lymphoma occurring within the parotid glands of patients with Sjögren's disease, via the parotid biopsies, that were not identifiable with the labial minor salivary gland biopsy. The parotid biopsy consistently identified each disease entity in an earlier stage, and with more evident histopathology. Neither technique showed appreciable morbidity. Three of 77 patients showed a sensory loss related to labial salivary gland biopsy. No sensory or motor nerve loss was associated with the parotid biopsy.

Entities:  

Mesh:

Year:  1988        PMID: 3397971

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  12 in total

1.  Comparison of labial and sublingual salivary gland biopsies in the diagnosis of Sjögren's syndrome.

Authors:  Y L Pennec; J P Leroy; J Jouquan; A Lelong; P Katsikis; P Youinou
Journal:  Ann Rheum Dis       Date:  1990-01       Impact factor: 19.103

2.  Coexisting primary Sjögren's syndrome and sarcoidosis: coincidence, mutually exclusive conditions or syndrome?

Authors:  T Santiago; M Santiago; J Rovisco; J Ferreira; C Duarte; A Malcata; J A P Da Silva
Journal:  Rheumatol Int       Date:  2014-04-28       Impact factor: 2.631

3.  [Sensory neuronopathy of Sjögren's syndrome. A diagnostic challenge].

Authors:  D Czell; R Baldinger; W Jochum; M Weber
Journal:  Nervenarzt       Date:  2012-02       Impact factor: 1.214

Review 4.  [Is bioptic assurance reasonable in patients with Sjögren's syndrome? From focus score to diagnosing vasculitides].

Authors:  V Krenn; M Jakobs; J Kriegsmann; M G Krukemeyer; A Rieger
Journal:  Z Rheumatol       Date:  2010-02       Impact factor: 1.372

5.  [Labial salivary gland biopsy in Sjögren's syndrome].

Authors:  A Dankof; L Morawietz; E Feist
Journal:  Pathologe       Date:  2006-11       Impact factor: 1.011

6.  Microbiology and Management of Sialadenitis.

Authors:  Patrick J. Bradley
Journal:  Curr Infect Dis Rep       Date:  2002-06       Impact factor: 3.725

7.  Local complications associated with labial salivary gland biopsy for diagnosis of Sjögren's Syndrome: A retrospective cohort study.

Authors:  Elena M Varoni; Gabriele Villani; Niccolò Lombardi; Alberto Pispero; Giovanni Lodi; Andrea Sardella; Daniela Uglietti
Journal:  J Clin Exp Dent       Date:  2020-08-01

8.  The European Community Study Group on diagnostic criteria for Sjögren's syndrome. Sensitivity and specificity of tests for ocular and oral involvement in Sjögren's syndrome.

Authors:  C Vitali; H M Moutsopoulos; S Bombardieri
Journal:  Ann Rheum Dis       Date:  1994-10       Impact factor: 19.103

9.  A comparison of clinical, pathological and radiological findings with magnetic resonance imaging studies of lymphomas in patients with Sjögren's syndrome.

Authors:  G Grevers; S Ihrler; T J Vogl; M Weiss
Journal:  Eur Arch Otorhinolaryngol       Date:  1994       Impact factor: 2.503

10.  A follow-up study of minimally invasive lip biopsy in the diagnosis of Sjögren's syndrome.

Authors:  Heikki Teppo; Matti Revonta
Journal:  Clin Rheumatol       Date:  2006-11-25       Impact factor: 3.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.